The Experts below are selected from a list of 18777 Experts worldwide ranked by ideXlab platform

Laura Mauri - One of the best experts on this subject based on the ideXlab platform.

  • 2017 esc focused update on Dual Antiplatelet Therapy in coronary artery disease developed in collaboration with eacts the task force for Dual Antiplatelet Therapy in coronary artery disease of the european society of cardiology esc and of the europea
    European Heart Journal, 2018
    Co-Authors: Marco Valgimigli, Hector Bueno, Robert A Byrne, Jeanphilippe Collet, F Costa, Anders Jeppsson, Peter Juni, Adnan Kastrati, Philippe Kolh, Laura Mauri
    Abstract:

    2017 ESC focused update on Dual Antiplatelet Therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for Dual Antiplatelet Therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

  • lesion complexity and outcomes of extended Dual Antiplatelet Therapy after percutaneous coronary intervention
    Journal of the American College of Cardiology, 2017
    Co-Authors: Robert W. Yeh, Laura Mauri, Dean J Kereiakes, Donald E. Cutlip, Joseph M. Massaro, Gabriel P Steg, Kevin Croce, Dapt Study Investigators
    Abstract:

    Abstract Background Subjects undergoing coronary stenting with complex lesion anatomy may experience different risks and benefits with prolonged Dual Antiplatelet Therapy. Objectives The authors assessed the effect of 30 months versus 12 months of Dual Antiplatelet Therapy (DAPT) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-complex target lesions. Methods In the DAPT Study, combined myocardial infarction (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and randomized (n = 11,554) subjects. Complex lesions had any of the following characteristics: unprotected left main, >2 lesions/vessel, length ≥30 mm, bifurcation with side branch ≥2.5 mm, vein bypass graft, or thrombus-containing lesion. Events were evaluated according to increasing number of complexity characteristics and compared according to DAPT score. Results Enrolled subjects with more complex target lesions had higher rates of MI or stent thrombosis in the first 12 months after PCI (3.9% vs. 2.4%; p  Conclusions Complex target-lesion anatomy is associated with increased ischemic events, particularly within the first year after PCI. Among those without events in the first 12 months, the benefits of extending DAPT were similar in subjects with and without complex lesions. A high DAPT score identified those experiencing the most benefit from extended treatment among patients with and without complex anatomy. (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938)

  • Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study
    JACC. Cardiovascular interventions, 2017
    Co-Authors: Eric A. Secemsky, Laura Mauri, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Patricia Apruzzese, Dual Antiplatelet Therapy Study Investigators
    Abstract:

    Abstract Objectives This study sought to determine whether patients with peripheral arterial disease (PAD) experience different reductions in ischemic event and increases in bleeding events with extended duration Dual Antiplatelet Therapy versus those without PAD. Background Patients with PAD have increased ischemic and bleeding risks after coronary stenting. Methods The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin Therapy for an additional 18 months versus aspirin Therapy alone. The effects of continued thienopyridine on myocardial infarction (MI) or stent thrombosis, major adverse cardiovascular and cerebrovascular events (death, MI, or stroke) and bleeding (GUSTO [Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries] moderate or severe) were assessed among those with versus without PAD. Results Among 11,648 randomized patients, 649 (5.57%) had PAD. Between 12 and 30 months, randomized patients with PAD had higher rates of MI/stent thrombosis (6.03% vs. 2.92%; p  Conclusions Among patients undergoing coronary stenting, those with PAD have more ischemic and bleeding events versus those without PAD. Extended duration Dual Antiplatelet Therapy is associated with consistent ischemic benefit and bleeding harm among patients with and without PAD.

  • Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Circulation, 2016
    Co-Authors: Charles D. Resor, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Ashwin S. Nathan, Wen-hua Hsieh, Laura Mauri
    Abstract:

    Background:Continued Dual Antiplatelet Therapy and optimal medical Therapy (OMT) improve outcomes in selected patient populations with established coronary heart disease, but whether OMT modifies t...

  • BENEFIT AND RISK OF Dual Antiplatelet Therapy IN FEMALES: DAPT STUDY RESULTS
    Journal of the American College of Cardiology, 2016
    Co-Authors: Natalia Berry, Dean J Kereiakes, Robert W. Yeh, Philippe Gabriel Steg, Donald E. Cutlip, Wen-hua Hsieh, Joseph Massaro, Laura Mauri
    Abstract:

    Females in the DAPT Study had attenuated benefit for reduction in myocardial infarction (MI) with continued thienopyridine Therapy beyond 12m when compared with males (interaction p =0.03). Whether the risk/benefit relationship of prolonged Dual Antiplatelet Therapy differs for females is unknown.

Marco Valgimigli - One of the best experts on this subject based on the ideXlab platform.

  • 2017 esc focused update on Dual Antiplatelet Therapy in coronary artery disease developed in collaboration with eacts the task force for Dual Antiplatelet Therapy in coronary artery disease of the european society of cardiology esc and of the europea
    European Heart Journal, 2018
    Co-Authors: Marco Valgimigli, Hector Bueno, Robert A Byrne, Jeanphilippe Collet, F Costa, Anders Jeppsson, Peter Juni, Adnan Kastrati, Philippe Kolh, Laura Mauri
    Abstract:

    2017 ESC focused update on Dual Antiplatelet Therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for Dual Antiplatelet Therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

  • Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
    Journal of the American College of Cardiology, 2016
    Co-Authors: Gennaro Giustino, Marco Valgimigli, Alaide Chieffo, Tullio Palmerini, Fausto Feres, Alexandre Abizaid, Ricardo A. Costa, Myeong-ki Hong, Byeong-keuk Kim, Yangsoo Jang
    Abstract:

    AbstractBackground: Optimal upfront Dual Antiplatelet Therapy (DAPT) duration after complex percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear.Objectives: This ...

  • short versus long term duration of Dual Antiplatelet Therapy after coronary stenting a randomized multicenter trial
    Circulation, 2012
    Co-Authors: Marco Valgimigli, Gianluca Campo, Monia Monti, Pascal Vranckx, Gianfranco Percoco, Carlo Tumscitz, Fausto Castriota, Federico Colombo, Matteo Tebaldi, Giuseppe Fuca
    Abstract:

    Background—The optimal duration of Dual-Antiplatelet Therapy and the risk-benefit ratio for long-term Dual-Antiplatelet Therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of Dual-Antiplatelet Therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration–approved drug-eluting or bare-metal stents. Methods and Results—We randomly assigned 2013 patients to receive bare-metal, zotarolimus-eluting, paclitaxel-eluting, or everolimus-eluting stent implantation. At 30 days, patients in each stent group were randomly allocated to receive up to 6 or 24 months of clopidogrel Therapy in addition to aspirin. The primary end point was a composite of death of any cause, myocardial infarction, or cerebrovascular accident. The cumulative risk of the primary outcome at 2 years was 10.1% with 24-month Dual-Antiplatelet Therapy compared with 10.0% with 6-month Dual-Antiplatelet Therapy (hazard ratio, 0.98; 95% confidenc...

  • short versus long term duration of Dual Antiplatelet Therapy after coronary stenting a randomized multicenter trial
    Circulation, 2012
    Co-Authors: Marco Valgimigli, Gianluca Campo, Monia Monti, Pascal Vranckx, Gianfranco Percoco, Carlo Tumscitz, Fausto Castriota, Federico Colombo, Matteo Tebaldi, Giuseppe Fuca
    Abstract:

    Background The optimal duration of Dual-Antiplatelet Therapy and the risk-benefit ratio for long-term Dual-Antiplatelet Therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of Dual-Antiplatelet Therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents. Methods and results We randomly assigned 2013 patients to receive bare-metal, zotarolimus-eluting, paclitaxel-eluting, or everolimus-eluting stent implantation. At 30 days, patients in each stent group were randomly allocated to receive up to 6 or 24 months of clopidogrel Therapy in addition to aspirin. The primary end point was a composite of death of any cause, myocardial infarction, or cerebrovascular accident. The cumulative risk of the primary outcome at 2 years was 10.1% with 24-month Dual-Antiplatelet Therapy compared with 10.0% with 6-month Dual-Antiplatelet Therapy (hazard ratio, 0.98; 95% confidence interval, 0.74-1.29; P=0.91). The indiviDual risks of death, myocardial infarction, cerebrovascular accident, or stent thrombosis did not differ between the study groups; however, there was a consistently greater risk of hemorrhage in the 24-month clopidogrel group according to all prespecified bleeding definitions, including the recently proposed Bleeding Academic Research Consortium classification. Conclusions A regimen of 24 months of clopidogrel Therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00611286.

Giuseppe Fuca - One of the best experts on this subject based on the ideXlab platform.

  • short versus long term duration of Dual Antiplatelet Therapy after coronary stenting a randomized multicenter trial
    Circulation, 2012
    Co-Authors: Marco Valgimigli, Gianluca Campo, Monia Monti, Pascal Vranckx, Gianfranco Percoco, Carlo Tumscitz, Fausto Castriota, Federico Colombo, Matteo Tebaldi, Giuseppe Fuca
    Abstract:

    Background—The optimal duration of Dual-Antiplatelet Therapy and the risk-benefit ratio for long-term Dual-Antiplatelet Therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of Dual-Antiplatelet Therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration–approved drug-eluting or bare-metal stents. Methods and Results—We randomly assigned 2013 patients to receive bare-metal, zotarolimus-eluting, paclitaxel-eluting, or everolimus-eluting stent implantation. At 30 days, patients in each stent group were randomly allocated to receive up to 6 or 24 months of clopidogrel Therapy in addition to aspirin. The primary end point was a composite of death of any cause, myocardial infarction, or cerebrovascular accident. The cumulative risk of the primary outcome at 2 years was 10.1% with 24-month Dual-Antiplatelet Therapy compared with 10.0% with 6-month Dual-Antiplatelet Therapy (hazard ratio, 0.98; 95% confidenc...

  • short versus long term duration of Dual Antiplatelet Therapy after coronary stenting a randomized multicenter trial
    Circulation, 2012
    Co-Authors: Marco Valgimigli, Gianluca Campo, Monia Monti, Pascal Vranckx, Gianfranco Percoco, Carlo Tumscitz, Fausto Castriota, Federico Colombo, Matteo Tebaldi, Giuseppe Fuca
    Abstract:

    Background The optimal duration of Dual-Antiplatelet Therapy and the risk-benefit ratio for long-term Dual-Antiplatelet Therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of Dual-Antiplatelet Therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents. Methods and results We randomly assigned 2013 patients to receive bare-metal, zotarolimus-eluting, paclitaxel-eluting, or everolimus-eluting stent implantation. At 30 days, patients in each stent group were randomly allocated to receive up to 6 or 24 months of clopidogrel Therapy in addition to aspirin. The primary end point was a composite of death of any cause, myocardial infarction, or cerebrovascular accident. The cumulative risk of the primary outcome at 2 years was 10.1% with 24-month Dual-Antiplatelet Therapy compared with 10.0% with 6-month Dual-Antiplatelet Therapy (hazard ratio, 0.98; 95% confidence interval, 0.74-1.29; P=0.91). The indiviDual risks of death, myocardial infarction, cerebrovascular accident, or stent thrombosis did not differ between the study groups; however, there was a consistently greater risk of hemorrhage in the 24-month clopidogrel group according to all prespecified bleeding definitions, including the recently proposed Bleeding Academic Research Consortium classification. Conclusions A regimen of 24 months of clopidogrel Therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00611286.

Robert W. Yeh - One of the best experts on this subject based on the ideXlab platform.

  • lesion complexity and outcomes of extended Dual Antiplatelet Therapy after percutaneous coronary intervention
    Journal of the American College of Cardiology, 2017
    Co-Authors: Robert W. Yeh, Laura Mauri, Dean J Kereiakes, Donald E. Cutlip, Joseph M. Massaro, Gabriel P Steg, Kevin Croce, Dapt Study Investigators
    Abstract:

    Abstract Background Subjects undergoing coronary stenting with complex lesion anatomy may experience different risks and benefits with prolonged Dual Antiplatelet Therapy. Objectives The authors assessed the effect of 30 months versus 12 months of Dual Antiplatelet Therapy (DAPT) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-complex target lesions. Methods In the DAPT Study, combined myocardial infarction (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and randomized (n = 11,554) subjects. Complex lesions had any of the following characteristics: unprotected left main, >2 lesions/vessel, length ≥30 mm, bifurcation with side branch ≥2.5 mm, vein bypass graft, or thrombus-containing lesion. Events were evaluated according to increasing number of complexity characteristics and compared according to DAPT score. Results Enrolled subjects with more complex target lesions had higher rates of MI or stent thrombosis in the first 12 months after PCI (3.9% vs. 2.4%; p  Conclusions Complex target-lesion anatomy is associated with increased ischemic events, particularly within the first year after PCI. Among those without events in the first 12 months, the benefits of extending DAPT were similar in subjects with and without complex lesions. A high DAPT score identified those experiencing the most benefit from extended treatment among patients with and without complex anatomy. (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938)

  • Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study
    JACC. Cardiovascular interventions, 2017
    Co-Authors: Eric A. Secemsky, Laura Mauri, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Patricia Apruzzese, Dual Antiplatelet Therapy Study Investigators
    Abstract:

    Abstract Objectives This study sought to determine whether patients with peripheral arterial disease (PAD) experience different reductions in ischemic event and increases in bleeding events with extended duration Dual Antiplatelet Therapy versus those without PAD. Background Patients with PAD have increased ischemic and bleeding risks after coronary stenting. Methods The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin Therapy for an additional 18 months versus aspirin Therapy alone. The effects of continued thienopyridine on myocardial infarction (MI) or stent thrombosis, major adverse cardiovascular and cerebrovascular events (death, MI, or stroke) and bleeding (GUSTO [Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries] moderate or severe) were assessed among those with versus without PAD. Results Among 11,648 randomized patients, 649 (5.57%) had PAD. Between 12 and 30 months, randomized patients with PAD had higher rates of MI/stent thrombosis (6.03% vs. 2.92%; p  Conclusions Among patients undergoing coronary stenting, those with PAD have more ischemic and bleeding events versus those without PAD. Extended duration Dual Antiplatelet Therapy is associated with consistent ischemic benefit and bleeding harm among patients with and without PAD.

  • Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Circulation, 2016
    Co-Authors: Charles D. Resor, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Ashwin S. Nathan, Wen-hua Hsieh, Laura Mauri
    Abstract:

    Background:Continued Dual Antiplatelet Therapy and optimal medical Therapy (OMT) improve outcomes in selected patient populations with established coronary heart disease, but whether OMT modifies t...

  • BENEFIT AND RISK OF Dual Antiplatelet Therapy IN FEMALES: DAPT STUDY RESULTS
    Journal of the American College of Cardiology, 2016
    Co-Authors: Natalia Berry, Dean J Kereiakes, Robert W. Yeh, Philippe Gabriel Steg, Donald E. Cutlip, Wen-hua Hsieh, Joseph Massaro, Laura Mauri
    Abstract:

    Females in the DAPT Study had attenuated benefit for reduction in myocardial infarction (MI) with continued thienopyridine Therapy beyond 12m when compared with males (interaction p =0.03). Whether the risk/benefit relationship of prolonged Dual Antiplatelet Therapy differs for females is unknown.

  • Reply : Analysis of Dual Antiplatelet Therapy
    Journal of the American College of Cardiology, 2015
    Co-Authors: Robert W. Yeh, Dean J Kereiakes, Laura Mauri
    Abstract:

    We thank Dr. Ganeshan and colleagues for their interest in our paper [(1)][1]. In our subgroup analysis of the DAPT Study (Dual Antiplatelet Therapy Study) [(1)][1], continued thienopyridine Therapy beyond 12 months after coronary stent placement provided consistent reductions in ischemic endpoints

Dean J Kereiakes - One of the best experts on this subject based on the ideXlab platform.

  • lesion complexity and outcomes of extended Dual Antiplatelet Therapy after percutaneous coronary intervention
    Journal of the American College of Cardiology, 2017
    Co-Authors: Robert W. Yeh, Laura Mauri, Dean J Kereiakes, Donald E. Cutlip, Joseph M. Massaro, Gabriel P Steg, Kevin Croce, Dapt Study Investigators
    Abstract:

    Abstract Background Subjects undergoing coronary stenting with complex lesion anatomy may experience different risks and benefits with prolonged Dual Antiplatelet Therapy. Objectives The authors assessed the effect of 30 months versus 12 months of Dual Antiplatelet Therapy (DAPT) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-complex target lesions. Methods In the DAPT Study, combined myocardial infarction (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and randomized (n = 11,554) subjects. Complex lesions had any of the following characteristics: unprotected left main, >2 lesions/vessel, length ≥30 mm, bifurcation with side branch ≥2.5 mm, vein bypass graft, or thrombus-containing lesion. Events were evaluated according to increasing number of complexity characteristics and compared according to DAPT score. Results Enrolled subjects with more complex target lesions had higher rates of MI or stent thrombosis in the first 12 months after PCI (3.9% vs. 2.4%; p  Conclusions Complex target-lesion anatomy is associated with increased ischemic events, particularly within the first year after PCI. Among those without events in the first 12 months, the benefits of extending DAPT were similar in subjects with and without complex lesions. A high DAPT score identified those experiencing the most benefit from extended treatment among patients with and without complex anatomy. (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938)

  • Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study
    JACC. Cardiovascular interventions, 2017
    Co-Authors: Eric A. Secemsky, Laura Mauri, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Patricia Apruzzese, Dual Antiplatelet Therapy Study Investigators
    Abstract:

    Abstract Objectives This study sought to determine whether patients with peripheral arterial disease (PAD) experience different reductions in ischemic event and increases in bleeding events with extended duration Dual Antiplatelet Therapy versus those without PAD. Background Patients with PAD have increased ischemic and bleeding risks after coronary stenting. Methods The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin Therapy for an additional 18 months versus aspirin Therapy alone. The effects of continued thienopyridine on myocardial infarction (MI) or stent thrombosis, major adverse cardiovascular and cerebrovascular events (death, MI, or stroke) and bleeding (GUSTO [Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries] moderate or severe) were assessed among those with versus without PAD. Results Among 11,648 randomized patients, 649 (5.57%) had PAD. Between 12 and 30 months, randomized patients with PAD had higher rates of MI/stent thrombosis (6.03% vs. 2.92%; p  Conclusions Among patients undergoing coronary stenting, those with PAD have more ischemic and bleeding events versus those without PAD. Extended duration Dual Antiplatelet Therapy is associated with consistent ischemic benefit and bleeding harm among patients with and without PAD.

  • Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Circulation, 2016
    Co-Authors: Charles D. Resor, Dean J Kereiakes, Robert W. Yeh, Donald E. Cutlip, P. Gabriel Steg, Joseph M. Massaro, Ashwin S. Nathan, Wen-hua Hsieh, Laura Mauri
    Abstract:

    Background:Continued Dual Antiplatelet Therapy and optimal medical Therapy (OMT) improve outcomes in selected patient populations with established coronary heart disease, but whether OMT modifies t...

  • BENEFIT AND RISK OF Dual Antiplatelet Therapy IN FEMALES: DAPT STUDY RESULTS
    Journal of the American College of Cardiology, 2016
    Co-Authors: Natalia Berry, Dean J Kereiakes, Robert W. Yeh, Philippe Gabriel Steg, Donald E. Cutlip, Wen-hua Hsieh, Joseph Massaro, Laura Mauri
    Abstract:

    Females in the DAPT Study had attenuated benefit for reduction in myocardial infarction (MI) with continued thienopyridine Therapy beyond 12m when compared with males (interaction p =0.03). Whether the risk/benefit relationship of prolonged Dual Antiplatelet Therapy differs for females is unknown.

  • Reply : Analysis of Dual Antiplatelet Therapy
    Journal of the American College of Cardiology, 2015
    Co-Authors: Robert W. Yeh, Dean J Kereiakes, Laura Mauri
    Abstract:

    We thank Dr. Ganeshan and colleagues for their interest in our paper [(1)][1]. In our subgroup analysis of the DAPT Study (Dual Antiplatelet Therapy Study) [(1)][1], continued thienopyridine Therapy beyond 12 months after coronary stent placement provided consistent reductions in ischemic endpoints